Biopharma Business

Tag "Alecensa"

European Commission conditionally approves Roche’s cancer drug Alecensa

Roche’s oral ALK inhibitor, Alecensa, has been conditionally approved in the European Union as a monotherapy for anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (NSCLC) in adults who were

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here